Lilly said in an open letter that it was "deeply concerned" about growing online sales and social media posts involving phony or compounded versions of tirzepatide, the active ingredient behind its drugs Mounjaro and Zepbound.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/xaTYVpZ
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment